Advertisement

Topics

Human medicines European public assessment report (EPAR): Capecitabine Teva, capecitabine, Colonic Neoplasms,Breast Neoplasms,Colorectal Neoplasms,Stomach Neoplasms, Date of authorisation: 20/04/2012, Revision: 10, Status: Authorised

12:53 EDT 9 Jul 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Capecitabine Teva, capecitabine, Colonic Neoplasms,Breast Neoplasms,Colorectal Neoplasms,Stomach Neoplasms, Date of authorisation: 20/04/2012, Revision: 10, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Capecitabine Teva, capecitabine, Colonic Neoplasms,Breast Neoplasms,Colorectal Neoplasms,Stomach Neoplasms, Date of authorisation: 20/04/2012, Revision: 10, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Capecitabine Teva, capecitabine, Colonic Neoplasms,Breast Neoplasms,Colorectal Neoplasms,Stomach Neoplasms, Date of authorisation: 20/04/2012, Revision: 10, Status: Authorised"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...